, where there would no longer be a significant public market for our common stock ) . however because the contractual formula used to determine the cash settlement value of the embedded put requires use of certain assumptions , the cash settlement value of the embedded put can differ from the fair value of the unexercised embedded call option at the time the embedded put option is exercised . specifically , the put rights would be triggered upon the happening of a “ fundamental transaction ” ( as defined below ) that also is ( 1 ) an all cash transaction ; ( 2 ) a “ rule 13e-3 transaction ” under the exchange act ( where the company would be taken private ) ; or ( 3 ) a transaction involving a person or entity not traded on a national securities exchange . “ fundamental transactions ” include ( i ) a merger or consolidation of the company with or into another person or entity ; ( ii ) a sale , lease , license , transfer or other disposition of all or substantially all of the company 's assets ; ( iii ) any purchase offer , tender offer or exchange offer in which holders of company common stock are permitted to sell , tender or exchange their shares for other securities , cash or property , which offer has been accepted by the holders of 50 % or more of the company 's outstanding common stock ; ( iv ) a reclassification , reorganization or recapitalization of the common stock pursuant to which the common stock is effectively converted into or exchanged for other securities , cash or property ; or ( v ) a stock purchase or other business combination with another person or entity is effected pursuant to which such other person or entity acquires more than 50 % of the outstanding shares of common stock . pursuant to the warrants , the put rights enable the warrant holders to receive cash in the amount of the black-scholes-merton value obtained from the “ ov ” function on bloomberg , l.p. ( “ bloomberg ” ) determined as of the day of consummation of the applicable fundamental transaction for pricing purposes and reflecting ( a ) a risk-free interest rate corresponding to the u.s. treasury rate for a period equal to the time between the date of the public announcement of the applicable fundamental transaction and the warrant expiration date , ( b ) an expected volatility equal to the greater of 100 % and the 100 day volatility obtained from the hvt function on bloomberg as of the trading day immediately following the public announcement of the applicable fundamental transaction , ( c ) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash , if any , plus the value of any non-cash consideration , if any , being offered in such fundamental transaction and ( d ) a remaining option time equal to the time between the date of the public announcement of the applicable fundamental transaction and the warrant expiration date . the company recomputes the fair value of the warrants at the end of each quarterly reporting period . such value computation includes subjective input assumptions that are consistently applied each period . if the company were to alter its assumptions or the numbers input based on such assumptions , the resulting fair value could be materially different . the warrants expired during 2014 . 30 the company utilized the following assumptions to estimate the fair value of the may 10 , 2009 , may 18 , 2009 and may 21 , 2009 warrants : replace_table_token_7_th the significant assumptions using the monte carlo simulation approach for valuation of the warrants are : ( i ) risk-free interest rate . the risk-free interest rates for the warrants are based on u.s treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants . ( ii ) expected holding period . the expected holding period represents the period of time that the warrants are expected to be outstanding until they are exercised . the company utilizes the remaining contractual term of the warrants at each valuation date as the expected holding period . ( iii ) expected volatility . expected stock volatility is based on daily observations of the company 's historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made . ( iv ) expected dividend yield . expected dividend yield is based on the company 's anticipated dividend payments over the remaining expected holding period . as the company has never issued dividends , the expected dividend yield is $ -0- and this assumption will be continued in future calculations unless the company changes its dividend policy . ( v ) expected probability of a fundamental transaction . the possibility of the occurrence of a fundamental transaction triggering a put right is extremely remote . as discussed above , a put right would only arise if a fundamental transaction 1 ) is an all cash transaction ; ( 2 ) results in the company going private ; or ( 3 ) is a transaction involving a person or entity not traded on a national securities exchange . story_separator_special_tag there can be no assurances that , if needed , we will raise adequate funds from these or other sources , which may have a material adverse effect on our ability to develop our products . also , we have the ability to curtail discretionary spending , including some research and development activities , if required to conserve cash . replace_table_token_8_th certain relationships and related transactions refer to part iii , item 13 - “ certain relationships and related transactions , and director independence . ” new accounting pronouncements refer to “ note 2 ( i ) – recent accounting standards and pronouncements ” under notes to consolidated financial statements . disclosure about off-balance sheet arrangements none . 36 critical accounting policies financial reporting release no . 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements . our significant accounting policies are described in the notes to consolidated financial statements . the significant accounting policies that we believe are most critical to aid in fully understanding our reported financial results are the following : revenue revenue from the sale of ampligen® under cost recovery clinical treatment protocols approved by the fda is recognized when the treatment is provided to the patient . revenues from the sale of product are recognized when the product is delivered , as title is then transferred to the customer . we have no other obligation associated with our products once shipment has been accepted by the customer inventories we use the lower of first-in , first-out ( “ fifo ” ) cost or market method of accounting for inventory . patents and trademarks patents and trademarks are stated at cost ( primarily legal fees ) and are amortized using the straight-line method over the estimated useful life of 17 years . we review our patents and trademark rights periodically to determine whether they have continuing value . such review includes an analysis of the patent and trademark 's ultimate revenue and profitability potential . in addition , management 's review addresses whether each patent continues to fit into our strategic business plans . long-lived assets the company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable . factors that the company considers in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations , significant negative industry or economic trends , and significant changes or planned changes in its use of the assets . the company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows . if an asset grouping 's carrying value is not recoverable through the related undiscounted cash flows , the asset grouping is considered to be impaired . the company measures the impairment by comparing the difference between the asset grouping 's carrying value and its fair value . long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized . impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows . the company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings . in addition , as the company reviews its manufacturing process and other manufacturing planning decisions , the company must make subjective judgments regarding the remaining useful lives of assets . when the company determines that the useful lives of assets are shorter than the company had originally estimated , it accelerates the rate of depreciation over the assets ' new , shorter useful lives . stock-based compensation under fasb asc 718-compensation-stock compensation ( “ asc 718 ” ) share-based compensation cost is measured at the grant date , based on the estimated fair value of the award , and is recognized as expense over the requisite service period . we adopted the provisions of asc-718 , using a modified prospective application . under this method , compensation cost is recognized for all share-based payments granted , modified or settled after the date of adoption , as well as for any unvested awards that were granted prior to the date of adoption . the fair value of each option award is estimated on the date of grant using a black-scholes-merton pricing option valuation model . expected volatility is based on the historical volatility of the price of our common stock . the risk-free interest rate is based on u.s. treasury issues with a term equal to the expected life of the option . we use historical data to estimate expected dividend yield , expected life , which represents the period of time the options are expected to be outstanding until they are exercised , and forfeiture rates . redeemable warrants 37 we utilize the guidance contained in asc 480 ( formerly sfas 150 ) in the determination of whether to record warrants and options as equity and or liability . if the guidance of asc 480 is deemed inconclusive , we continue our analysis utilizing asc 815 ( formerly eitf 00-19 ) . our method of recording the related value attempts to be consistent with the standards as defined by the financial accounting standards board utilizing the concept of “ fair value ” from asc 820-10-55-1 that states that any fair value measurement requires that the reporting entity to determine the valuation technique ( s ) appropriate for the measurement , considering the availability of data with which to develop inputs that represent the assumptions that market participants would use in pricing the asset or liability and the level in the fair value hierarchy within which the inputs fall . we recomputed the value of the redeemable warrants

liquidity and capital resources cash used in operating activities for the year ended december 31 , 2014 was approximately $ 13,918,000 compared to approximately $ 16,830,000 for the same period in 2013 , a decrease of $ 2,912,000 or 17 % . excluding the proceeds from the sale of new jersey net operating loss carry-forwards , cash used in operating activities for the year ended december 31 , 2014 decreased by approximately $ 2,472,000 or 14 % over the comparable period in 2013. the primary reason for this decrease in 2014 was due to the january 2013 payout of 2012 employee and strategic consultant bonuses for approximately $ 2,196,000 reflected in accrued expenses and a decrease in accounts payable due to the timing of payments of approximately $ 1,486,000 as of december 31 , 2014 and 2013 , respectively . this was offset by the write off of inventory valued at $ 453,000 and the impairment of other than temporary marketable securities of $ 800,000 during the year ended december 31 , 2013. as of december 31 , 2014 , we had approximately $ 16,108,000 in cash , cash equivalents and marketable securities inclusive of approximately $ 13,952,000 in marketable securities , or a decrease of approximately $ 2,086,000 from december 31 , 2013. if we are unable to commercialize and sell ampligen® or alferon® ldo and or recommence material sales of alferon n injection® , our operations , financial position and liquidity may be adversely impacted , and additional financing may be required . however , there is no assurance that such financing will be available . in its february 1 , 2013 crl , the fda communicated that we should conduct at least one additional clinical trial , complete various nonclinical studies and perform a number of data analyses . until we undertake the end-of-review conference ( s ) with the fda , we are unable to reasonably estimate the nature , costs , necessary efforts to obtain fda clearance or anticipated completion dates of any additional clinical study or studies . please see “ part ii ; item 1a . risk factors ; “ we may require additional financing which may not be available .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources cash used in operating activities for the year ended december 31 , 2014 was approximately $ 13,918,000 compared to approximately $ 16,830,000 for the same period in 2013 , a decrease of $ 2,912,000 or 17 % . excluding the proceeds from the sale of new jersey net operating loss carry-forwards , cash used in operating activities for the year ended december 31 , 2014 decreased by approximately $ 2,472,000 or 14 % over the comparable period in 2013. the primary reason for this decrease in 2014 was due to the january 2013 payout of 2012 employee and strategic consultant bonuses for approximately $ 2,196,000 reflected in accrued expenses and a decrease in accounts payable due to the timing of payments of approximately $ 1,486,000 as of december 31 , 2014 and 2013 , respectively . this was offset by the write off of inventory valued at $ 453,000 and the impairment of other than temporary marketable securities of $ 800,000 during the year ended december 31 , 2013. as of december 31 , 2014 , we had approximately $ 16,108,000 in cash , cash equivalents and marketable securities inclusive of approximately $ 13,952,000 in marketable securities , or a decrease of approximately $ 2,086,000 from december 31 , 2013. if we are unable to commercialize and sell ampligen® or alferon® ldo and or recommence material sales of alferon n injection® , our operations , financial position and liquidity may be adversely impacted , and additional financing may be required . however , there is no assurance that such financing will be available . in its february 1 , 2013 crl , the fda communicated that we should conduct at least one additional clinical trial , complete various nonclinical studies and perform a number of data analyses . until we undertake the end-of-review conference ( s ) with the fda , we are unable to reasonably estimate the nature , costs , necessary efforts to obtain fda clearance or anticipated completion dates of any additional clinical study or studies . please see “ part ii ; item 1a . risk factors ; “ we may require additional financing which may not be available .
```    
 Suspicious Activity Report : , where there would no longer be a significant public market for our common stock ) . however because the contractual formula used to determine the cash settlement value of the embedded put requires use of certain assumptions , the cash settlement value of the embedded put can differ from the fair value of the unexercised embedded call option at the time the embedded put option is exercised . specifically , the put rights would be triggered upon the happening of a “ fundamental transaction ” ( as defined below ) that also is ( 1 ) an all cash transaction ; ( 2 ) a “ rule 13e-3 transaction ” under the exchange act ( where the company would be taken private ) ; or ( 3 ) a transaction involving a person or entity not traded on a national securities exchange . “ fundamental transactions ” include ( i ) a merger or consolidation of the company with or into another person or entity ; ( ii ) a sale , lease , license , transfer or other disposition of all or substantially all of the company 's assets ; ( iii ) any purchase offer , tender offer or exchange offer in which holders of company common stock are permitted to sell , tender or exchange their shares for other securities , cash or property , which offer has been accepted by the holders of 50 % or more of the company 's outstanding common stock ; ( iv ) a reclassification , reorganization or recapitalization of the common stock pursuant to which the common stock is effectively converted into or exchanged for other securities , cash or property ; or ( v ) a stock purchase or other business combination with another person or entity is effected pursuant to which such other person or entity acquires more than 50 % of the outstanding shares of common stock . pursuant to the warrants , the put rights enable the warrant holders to receive cash in the amount of the black-scholes-merton value obtained from the “ ov ” function on bloomberg , l.p. ( “ bloomberg ” ) determined as of the day of consummation of the applicable fundamental transaction for pricing purposes and reflecting ( a ) a risk-free interest rate corresponding to the u.s. treasury rate for a period equal to the time between the date of the public announcement of the applicable fundamental transaction and the warrant expiration date , ( b ) an expected volatility equal to the greater of 100 % and the 100 day volatility obtained from the hvt function on bloomberg as of the trading day immediately following the public announcement of the applicable fundamental transaction , ( c ) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash , if any , plus the value of any non-cash consideration , if any , being offered in such fundamental transaction and ( d ) a remaining option time equal to the time between the date of the public announcement of the applicable fundamental transaction and the warrant expiration date . the company recomputes the fair value of the warrants at the end of each quarterly reporting period . such value computation includes subjective input assumptions that are consistently applied each period . if the company were to alter its assumptions or the numbers input based on such assumptions , the resulting fair value could be materially different . the warrants expired during 2014 . 30 the company utilized the following assumptions to estimate the fair value of the may 10 , 2009 , may 18 , 2009 and may 21 , 2009 warrants : replace_table_token_7_th the significant assumptions using the monte carlo simulation approach for valuation of the warrants are : ( i ) risk-free interest rate . the risk-free interest rates for the warrants are based on u.s treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants . ( ii ) expected holding period . the expected holding period represents the period of time that the warrants are expected to be outstanding until they are exercised . the company utilizes the remaining contractual term of the warrants at each valuation date as the expected holding period . ( iii ) expected volatility . expected stock volatility is based on daily observations of the company 's historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made . ( iv ) expected dividend yield . expected dividend yield is based on the company 's anticipated dividend payments over the remaining expected holding period . as the company has never issued dividends , the expected dividend yield is $ -0- and this assumption will be continued in future calculations unless the company changes its dividend policy . ( v ) expected probability of a fundamental transaction . the possibility of the occurrence of a fundamental transaction triggering a put right is extremely remote . as discussed above , a put right would only arise if a fundamental transaction 1 ) is an all cash transaction ; ( 2 ) results in the company going private ; or ( 3 ) is a transaction involving a person or entity not traded on a national securities exchange . story_separator_special_tag there can be no assurances that , if needed , we will raise adequate funds from these or other sources , which may have a material adverse effect on our ability to develop our products . also , we have the ability to curtail discretionary spending , including some research and development activities , if required to conserve cash . replace_table_token_8_th certain relationships and related transactions refer to part iii , item 13 - “ certain relationships and related transactions , and director independence . ” new accounting pronouncements refer to “ note 2 ( i ) – recent accounting standards and pronouncements ” under notes to consolidated financial statements . disclosure about off-balance sheet arrangements none . 36 critical accounting policies financial reporting release no . 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements . our significant accounting policies are described in the notes to consolidated financial statements . the significant accounting policies that we believe are most critical to aid in fully understanding our reported financial results are the following : revenue revenue from the sale of ampligen® under cost recovery clinical treatment protocols approved by the fda is recognized when the treatment is provided to the patient . revenues from the sale of product are recognized when the product is delivered , as title is then transferred to the customer . we have no other obligation associated with our products once shipment has been accepted by the customer inventories we use the lower of first-in , first-out ( “ fifo ” ) cost or market method of accounting for inventory . patents and trademarks patents and trademarks are stated at cost ( primarily legal fees ) and are amortized using the straight-line method over the estimated useful life of 17 years . we review our patents and trademark rights periodically to determine whether they have continuing value . such review includes an analysis of the patent and trademark 's ultimate revenue and profitability potential . in addition , management 's review addresses whether each patent continues to fit into our strategic business plans . long-lived assets the company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable . factors that the company considers in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations , significant negative industry or economic trends , and significant changes or planned changes in its use of the assets . the company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows . if an asset grouping 's carrying value is not recoverable through the related undiscounted cash flows , the asset grouping is considered to be impaired . the company measures the impairment by comparing the difference between the asset grouping 's carrying value and its fair value . long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized . impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows . the company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings . in addition , as the company reviews its manufacturing process and other manufacturing planning decisions , the company must make subjective judgments regarding the remaining useful lives of assets . when the company determines that the useful lives of assets are shorter than the company had originally estimated , it accelerates the rate of depreciation over the assets ' new , shorter useful lives . stock-based compensation under fasb asc 718-compensation-stock compensation ( “ asc 718 ” ) share-based compensation cost is measured at the grant date , based on the estimated fair value of the award , and is recognized as expense over the requisite service period . we adopted the provisions of asc-718 , using a modified prospective application . under this method , compensation cost is recognized for all share-based payments granted , modified or settled after the date of adoption , as well as for any unvested awards that were granted prior to the date of adoption . the fair value of each option award is estimated on the date of grant using a black-scholes-merton pricing option valuation model . expected volatility is based on the historical volatility of the price of our common stock . the risk-free interest rate is based on u.s. treasury issues with a term equal to the expected life of the option . we use historical data to estimate expected dividend yield , expected life , which represents the period of time the options are expected to be outstanding until they are exercised , and forfeiture rates . redeemable warrants 37 we utilize the guidance contained in asc 480 ( formerly sfas 150 ) in the determination of whether to record warrants and options as equity and or liability . if the guidance of asc 480 is deemed inconclusive , we continue our analysis utilizing asc 815 ( formerly eitf 00-19 ) . our method of recording the related value attempts to be consistent with the standards as defined by the financial accounting standards board utilizing the concept of “ fair value ” from asc 820-10-55-1 that states that any fair value measurement requires that the reporting entity to determine the valuation technique ( s ) appropriate for the measurement , considering the availability of data with which to develop inputs that represent the assumptions that market participants would use in pricing the asset or liability and the level in the fair value hierarchy within which the inputs fall . we recomputed the value of the redeemable warrants

